DoW Breast Cancer, Transformative Breast Cancer Consortium Award

The FY26 Transformative Breast Cancer Consortium Award, sponsored by the Defense Health Agency, offers $35 million for a single four-year project. This funding opportunity seeks highly integrated, multidisciplinary, and multi-institutional consortia to address significant breast cancer challenges, aiming to transform the lives of individuals affected by or at risk for the disease. Applications must propose innovative, paradigm-shifting research, with each consortium comprising a Consortium Director and three to four Project Team PIs, plus at least one breast cancer consumer advocate per project team. A two-step application process involves a pre-application due June 12, 2026, and a full application due September 30, 2026. Eligibility extends to U.S. and foreign, for-profit and nonprofit organizations, with specific requirements for PI commitment and a prohibition on certain types of research. The award emphasizes collaboration, real-time data sharing, and a robust administrative management plan, with a portion of the budget allocated for 'seed projects' and a program manager.